CRMD's DefenCath, the only FDA-approved antimicrobial catheter lock, saw higher outpatient dialysis use in the fourth quarter ...

From September 2024 to October 2025, there was a 26 percent reduction in infections in adult, pediatric, and neonatal ...

Drivers could face up to £1,000 fines and potential prosecution if they fail to report notifiable medical conditions or ...

CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases.

The Pitt season premiere, "7:00 a.m.," ignores clichés in favor of a gritty, realistic, and uncompromising take on the ...

The outlook includes $150 million to $170 million from DefenCath, with results weighted toward the first half of the year.

CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening ...

Under the leadership of Mr. Todisco, CorMedix has evolved from a single product, development stage company into a multi-product, diversified commercial operation with positive cashflow and a strong ...

Abstract: In current deep-learning-based multi-view stereo methods, feature extraction and cost volume regularization are two key steps that affect the reconstruction quality. Most current methods ...

The article " Why CorMedix Could be the Biopharma Name to Watch Early in 2026 " first appeared on MarketBeat.